PENTASA® (mesalazine)

PENTASA® is an original mesalazine with a PH resistant coat and gradual release of API throughout the whole gastrointestinal tract. PENTASA is indicated for the induction and maintaining of remission in patients with mildly to moderately active ulcerative colitis and Crohn disease. Three solid dosage forms of Pentasa are available in Russia: tablets, granules in sachet, and suppositories. This is currently the only high-dosage mesalazine registered in Russia: 1 suppository contains 1g of mesalazine and 1 sachet contains 2g of mesalazine

PENTASA® (mesalazine) is Ferring's product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn's disease).

PENTASA is prescribed to treat the mild to moderate symptoms of active IBD as well as being used widely as maintenance therapy to reduce the risk of recurrent attacks.

PENTASA is available orally as tablets and granules (sachets) within Europe and the rest of the world, excluding the USA. In the USA, Shire US, Inc. sells PENTASA under a trademark license from Ferring. Topical formulations (suppositories) is also available for administration via the rectum, allowing a high concentration of the drug to be in contact with areas of inflammation at the lower end of the digestive tract.

Oral PENTASA has a prolonged-release formulation, helping to ensure release of active mesalazine throughout the entire length of the intestine from the duodenum to the rectum. Topical PENTASA formulations (suppositories) enable active mesalazine to remain in contact with the inflamed mucosa for several hours.

All products passed Clinical Trials and registered in Russia.



Read more


Read more

Media Center

Read more